EMA domperidone safety review will consider 'sudden death' claims
This article was originally published in SRA
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee will consider claims by the French drug bulletin Prescrire that the anti-emetic drug domperidone may have caused as many as 120 sudden deaths in France alone last year1,2.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.